LY3540378 for Chronic Heart Failure
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called LY3540378 to see if it can help adults whose heart failure is getting worse even though their heart pumps normally. The goal is to find out if this medication can improve their heart function and safety.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How is the drug LY3540378 different from other treatments for chronic heart failure?
LY3540378 may offer a new approach by potentially improving heart function directly, unlike current treatments that mainly manage symptoms or reduce stress on the heart. This could be significant as no positive inotropes (drugs that increase heart muscle contraction) are currently approved for long-term use in heart failure.12345
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for adults with chronic heart failure who've had a recent worsening event requiring intravenous diuretics. They must have had a preserved ejection fraction (≥50%) documented within the last year and been on loop diuretics for at least 30 days prior to their worsening event. Exclusions include recent acute coronary events, uncorrected thyroid disease, certain cardiomyopathies, severe lung diseases like COPD, or planned heart surgeries.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive LY3540378 or placebo subcutaneously
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LY3540378
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University